SOMERVILLE, Mass. and WALTHAM, Mass., April 8, 2020 /PRNewswire/ — To enhance COVID-19 tracking and trending, Biobot Analytics is applying its technology to analyze biological data from sewers to help identify the spread of SARS-CoV-2, the virus causing COVID-19. Due to limited COVID-19 patient testing, many public health officials do not have the data required to determine the scope of the outbreak, model the pandemic accurately, or respond based on severity. Learn more about the program at https://www.biobot.io/covid19/.
Biobot’s wastewater analysis can help to increase modeling accuracy without direct interaction with an increasingly strained healthcare system. Biobot analysis provides communities with a dynamic virus map of pandemic changes such as the spread to new areas and a reduction in established hotspots.
New studies show that SARS-CoV-2 is shed in stool, meaning it’s collecting in sewer systems. “Wastewater epidemiology can help to gauge the level of COVID-19 infection because a broad community or area can be tested rapidly,” said Newsha Ghaeli, Biobot Analytics co-founder and president. “And by identifying SARS-CoV-2 in asymptomatic individuals, Biobot can help public health officials plan more effectively.”
Biobot is actively supporting COVID-19 epidemiology in two ways:
1) Establish protocols to test sewage for SARS-CoV-2. Biobot, along with researchers at MIT, Harvard, and Brigham and Women’s Hospital, announced a program to map COVID-19 nationally. The researchers are providing the work pro bono; communities only need to cover sample kit and shipping costs ($120 per sample). Communities will collect and ship their samples to Biobot.
2) Increase its automated sampling to run for seven consecutive days. Expanding sampling from one day to seven, along with additional product ruggedization, builds on an earlier Biobot prototype used during a successful pilot with a North Carolina municipality to improve its understanding of community opioid use.
To access product engineering and manufacturing support, Biobot contacted FORGE, a nonprofit organization established by Greentown Labs, the largest cleantech incubator in North America, to support product startups from initial prototyping and design through production.
Through FORGE, Biobot selected Boston Engineering to enhance its product capabilities and design for manufacturability. In 2019, Boston Engineering enhanced Biobot product design and manufactured 12 prototypes. The Biobot product roadmap includes producing advanced prototypes and making additional enhancements for scalable manufacturing.
“Working with Boston Engineering, through FORGE’s connection, has been transformative to our work,” said Mariana Matus, CEO and co-founder of Biobot Analytics.
“We are proud to help Biobot scale the availability of its system to provide public health officials with new levels of actionable insight,” said Mark Smithers, CTO of Boston Engineering.
About Biobot Analytics
Inspired by the potential of wastewater epidemiology, Biobot is the first company in the world to commercialize data from sewage. The company’s technology generates public health data that is naturally anonymized yielding unprecedented insight into the health of communities without collecting personal identifiable information. Biobot is headquartered in the Boston area and is available online at https://www.biobot.io/.
About Boston Engineering
Boston Engineering provides product design and engineering consulting from concept development through connected product capabilities. The company specializes in defense & security, medical devices, robotics, and commercial industries. Boston Engineering is also a reseller for PTC, ThingWorx, and Ansys. Founded in 1995, Boston Engineering is certified to ISO 9001:2015 and ISO 13485:2016 standards. The company is headquartered in Waltham, Mass., and is online at www.boston-engineering.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/biobot-launches-covid-19-detection-modeling-via-wastewater-analysis-301037713.html
SOURCE Boston Engineering
HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…
This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…
Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…
SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…
MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…